GSK Anoro Ellipta Appears Poised For Smooth Advisory Panel; Is First LAMA/LABA On Horizon?
This article was originally published in The Pink Sheet Daily
Candidate for first-approved LAMA/LABA combination for COPD heads to the Pulmonary-Allergy Drugs Advisory Committee as FDA questions whether safety is even a concern.
You may also be interested in...
The lead LAMA/LABA combination for COPD will be reviewed at the Sept. 10 session of the Pulmonary-Allergy Drugs Advisory Committee.
Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.
New drugs are hitting the COPD market, but largely offer incremental benefit over gold standards Advair and Spiriva. Given the modest efficacy improvement and increasingly price sensitive patients and payers, new higher-priced products may find the commercial market a challenge.